<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Hispolon treatment inhibited the invasive capabilities of HeLa and SiHa cells 
 <italic>via</italic> blocking ERK pathway (
 <xref rid="bib39" ref-type="bibr">Hsin et al., 2017</xref>). Hispolon exerts anti-metastatic effects by the inhibition of uPA (Urokinase plasminogen activator) 
 <italic>via</italic> the Akt pathway in nasopharyngeal cancer cells (
 <xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>). By reducing the expression of MMP-2, MMP-9 and uPA, hispolon inhibited the metastasis in SK-Hep1 cells (
 <xref rid="bib40" ref-type="bibr">Huang et al., 2010</xref>). Furthermore, hispolon suppresses invasive potential of cancer cells 
 <italic>via</italic> EMT inhibition. Therefore, hispolon may be a novel anti-metastatic agent (
 <xref rid="bib35" ref-type="bibr">Hong et al., 2017</xref>). As EMT has close association with drug resistance, further studies should also investigate whether hispolon has potential to sensitize cancer cells towards chemo-drugs.
</p>
